Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures (2022 - 2025)

Organogenesis Holdings (ORGO) has 4 years of Gains from Sales and Divestitures data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 14.32% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 14.32%, while the annual FY2025 figure was $1.6 million, 14.32% up from the prior year.
  • Gains from Sales and Divestitures reached $1.6 million in Q4 2025 per ORGO's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q4 2025 and bottomed at $239245.0 in Q2 2022.
  • Average Gains from Sales and Divestitures over 4 years is $984774.5, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 230.35% in 2024, then rose 10.67% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $249106.0 in 2022, then skyrocketed by 109.81% to $522651.0 in 2023, then skyrocketed by 174.53% to $1.4 million in 2024, then rose by 14.32% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.